2022
Genome-wide identification and analysis of prognostic features in human cancers
Smith JC, Sheltzer JM. Genome-wide identification and analysis of prognostic features in human cancers. Cell Reports 2022, 38: 110569. PMID: 35354049, PMCID: PMC9042322, DOI: 10.1016/j.celrep.2022.110569.Peer-Reviewed Original ResearchConceptsAdverse biomarkersSignificant prognostic biomarkerShorter survival timePromising therapeutic targetPatient survival dataPreclinical cancer researchPrognostic featuresAggressive malignancyClinical trialsPatient outcomesPatient riskPrognostic biomarkerSurvival timeTherapeutic targetSuccessful drug targetsClinical decisionCancerSurvival dataTherapeutic developmentHuman cancersBiomarkersBiomarker analysisDriver genesCancer researchCancer driver genes
2018
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
Giuliano C, Lin A, Smith J, Palladino A, Sheltzer J. MELK expression correlates with tumor mitotic activity but is not required for cancer growth. ELife 2018, 7: e32838. PMID: 29417930, PMCID: PMC5805410, DOI: 10.7554/elife.32838.Peer-Reviewed Original ResearchConceptsMaternal embryonic leucine zipper kinaseTumor mitotic activityCancer typesMitotic activityPoor clinical prognosisBreast cancer cell linesPromising therapeutic targetTriple-negative breast cancer cell linesEmbryonic leucine zipper kinaseMultiple cancer typesLeucine zipper kinaseCancer cell linesCytotoxic chemotherapyAggressive diseaseCancer patientsClinical prognosisMELK expressionTherapeutic targetChemotherapy resistanceCancer growthTumor growthAcute inhibitionMELK inhibitorExpression correlatesCancer-related processes